Year All202520242023202220212020201920182017 Inozyme Pharma Announces $73 Million Underwritten Offering Priced At-the-Market Apr 14, 2022 Inozyme Pharma Provides Update for Phase 1/2 Clinical Trials in ABCC6 Deficiency and ENPP1 Deficiency Apr 12, 2022 Inozyme Pharma to Present at the 21st Annual Needham Virtual Healthcare Conference Apr 06, 2022 Inozyme Pharma Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Patients with ENPP1 Deficiency Apr 04, 2022 Inozyme Pharma Reports Full Year 2021 Financial Results and Provides Business Highlights Mar 15, 2022 Inozyme Pharma Strengthens Management Team with Two Executive Appointments Mar 08, 2022 Inozyme Pharma to Present at Cowen 42nd Annual Health Care Conference Mar 01, 2022 Inozyme Pharma Announces Dosing of First Patient in First-in-Human Clinical Trial of INZ-701 in Patients with ENPP1 Deficiency Nov 15, 2021 Inozyme Pharma to Present at Upcoming Investor Conferences Nov 11, 2021 Inozyme Pharma Reports Third Quarter 2021 Financial Results and Provides Business Highlights Nov 09, 2021
Year All202520242023202220212020201920182017 Inozyme Pharma Announces $73 Million Underwritten Offering Priced At-the-Market Apr 14, 2022 Inozyme Pharma Provides Update for Phase 1/2 Clinical Trials in ABCC6 Deficiency and ENPP1 Deficiency Apr 12, 2022 Inozyme Pharma to Present at the 21st Annual Needham Virtual Healthcare Conference Apr 06, 2022 Inozyme Pharma Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Patients with ENPP1 Deficiency Apr 04, 2022 Inozyme Pharma Reports Full Year 2021 Financial Results and Provides Business Highlights Mar 15, 2022 Inozyme Pharma Strengthens Management Team with Two Executive Appointments Mar 08, 2022 Inozyme Pharma to Present at Cowen 42nd Annual Health Care Conference Mar 01, 2022 Inozyme Pharma Announces Dosing of First Patient in First-in-Human Clinical Trial of INZ-701 in Patients with ENPP1 Deficiency Nov 15, 2021 Inozyme Pharma to Present at Upcoming Investor Conferences Nov 11, 2021 Inozyme Pharma Reports Third Quarter 2021 Financial Results and Provides Business Highlights Nov 09, 2021
Inozyme Pharma Provides Update for Phase 1/2 Clinical Trials in ABCC6 Deficiency and ENPP1 Deficiency Apr 12, 2022
Inozyme Pharma Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Patients with ENPP1 Deficiency Apr 04, 2022
Inozyme Pharma Reports Full Year 2021 Financial Results and Provides Business Highlights Mar 15, 2022
Inozyme Pharma Announces Dosing of First Patient in First-in-Human Clinical Trial of INZ-701 in Patients with ENPP1 Deficiency Nov 15, 2021
Inozyme Pharma Reports Third Quarter 2021 Financial Results and Provides Business Highlights Nov 09, 2021